Compare GECC & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GECC | CSBR |
|---|---|---|
| Founded | 2016 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.3M | 65.4M |
| IPO Year | 2016 | 2015 |
| Metric | GECC | CSBR |
|---|---|---|
| Price | $4.90 | $4.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 91.1K | 6.2K |
| Earning Date | 11-02-2026 | 12-14-2026 |
| Dividend Yield | ★ 20.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | N/A | ★ $2,900,000.00 |
| Revenue This Year | N/A | $9.83 |
| Revenue Next Year | $5.98 | $8.50 |
| P/E Ratio | $49.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $4.52 |
| 52 Week High | $7.97 | $8.31 |
| Indicator | GECC | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 33.49 |
| Support Level | $4.73 | N/A |
| Resistance Level | $5.17 | $6.29 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 47.57 | 0.00 |
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.